Raising the bar for disclosure of industry payments to doctors

Menkes and colleagues argue that transparent reporting of drug industry payments to doctors is crucial to managing conflicts of interest. In 2022, New Zealand saw its first disclosures of financial relationships between drug companies and health professionals. While this was a step towards transparency, it was limited, with some payment types omitted. International comparisons show…

Read More

Endo to pay $2 bn to settle US charges on opioid crisis

Endo Health Solutions has agreed to pay $2 billion to settle civil and criminal charges related to mislabeling the pain reliever drug Opana, which contributed to the opioid epidemic. The agreement includes a criminal plea where the company admitted to mislabeling Opana, marketing it for non-medically accepted purposes, and misleading healthcare providers regarding its abuse…

Read More

Forever Chemicals Are Everywhere, But You Can Lower Your Risk

Long-lasting and harmful chemicals known as “forever chemicals” are widespread in everyday items like water bottles, cookware, and cosmetics, contaminating water, food, and homes. Studies link exposure to health issues, including cancer. Recent FDA regulations aim to limit harmful chemicals in food packaging, signaling progress. Consumers can reduce exposure by choosing unpackaged, organic foods, using…

Read More

Many European Cancer Drugs Offer No Added Benefit

A study from Utrecht University in the Netherlands found that many cancer drugs approved by the European Medicines Agency between 1995 and 2020 lack proof of added benefit. The researchers reported that a large proportion of these drugs offered minimal or no added benefit, especially those approved through fast-track pathways. The costs of these drugs…

Read More

Investigational oral drug sebetralstat provided on-demand relief during tissue swelling attacks from hereditary angioedema: Phase 3 study

An investigational oral drug called sebetralstat was found to provide on-demand relief for attacks of tissue swelling in patients with hereditary angioedema, according to a Phase 3 study. The study showed promising results in reducing symptoms of the condition. The drug may offer a new treatment option for patients experiencing these attacks. Cookies are used…

Read More

The Future of Innovation Metastatic Breast Cancer: 2024 Outlook

The annual San Antonio Breast Cancer meeting in 2023 highlighted advancements in metastatic breast cancer treatment, which affects 40,000 women and 4,000 men in the US annually. CDK4/6 inhibitors have improved progression-free survival, but resistance remains a challenge. New therapies like Olaparib, capivasertib, and everolimus are showing promise for resistant patients. Precision oncology screening is…

Read More
error: Content is protected !!